Literature DB >> 26453288

Identification of novel polyglutamine-expanded aggregation species in spinal and bulbar muscular atrophy.

Tamar R Berger1, Heather L Montie2, Pranav Jain3, Justin Legleiter3, Diane E Merry4.   

Abstract

Polyglutamine-repeat disorders are part of a larger family of neurodegenerative diseases characterized by protein misfolding and aggregation. In spinal and bulbar muscular atrophy (SBMA), polyglutamine expansion within the androgen receptor (AR) causes progressive debilitating muscular atrophy and lower motor neuron loss in males. Although soluble polyglutamine-expanded aggregation species are considered toxic intermediates in the aggregation process, relatively little is known about the spectrum of structures that are formed. Here we identify novel polyglutamine-expanded AR aggregates that are SDS-soluble and bind the toxicity-predicting antibody 3B5H10. Soluble, 3B5H10-reactive aggregation species exist in low-density conformations and are larger by atomic force microscopy, suggesting that they may be less compact than later-stage, insoluble aggregates. We demonstrate disease-relevance in vivo and draw correlations with toxicity in vitro. This article is part of a Special Issue entitled SI: Neuroprotection.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Androgen receptor; Polyglutamine; Protein aggregation; Spinal and bulbar muscular atrophy

Mesh:

Substances:

Year:  2015        PMID: 26453288      PMCID: PMC4681586          DOI: 10.1016/j.brainres.2015.09.033

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  37 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  Extraction of nucleic acid fragments from gels.

Authors:  Biji T Kurien; R Hal Scofield
Journal:  Anal Biochem       Date:  2002-03-01       Impact factor: 3.365

Review 3.  Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.

Authors:  Ronald Wetzel
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

4.  Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients.

Authors:  Christopher Grunseich; Kristen Zukosky; Ilona R Kats; Laboni Ghosh; George G Harmison; Laura C Bott; Carlo Rinaldi; Ke-lian Chen; Guibin Chen; Manfred Boehm; Kenneth H Fischbeck
Journal:  Neurobiol Dis       Date:  2014-06-09       Impact factor: 5.996

5.  Curvature enhances binding and aggregation of huntingtin at lipid membranes.

Authors:  Maxmore Chaibva; Kathleen A Burke; Justin Legleiter
Journal:  Biochemistry       Date:  2014-04-04       Impact factor: 3.162

6.  Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy.

Authors:  Masahisa Katsuno; Hiroaki Adachi; Akito Kume; Mei Li; Yuji Nakagomi; Hisayoshi Niwa; Chen Sang; Yasushi Kobayashi; Manabu Doyu; Gen Sobue
Journal:  Neuron       Date:  2002-08-29       Impact factor: 17.173

7.  Proteasome-mediated proteolysis of the polyglutamine-expanded androgen receptor is a late event in spinal and bulbar muscular atrophy (SBMA) pathogenesis.

Authors:  Erin M Heine; Tamar R Berger; Anna Pluciennik; Christopher R Orr; Lori Zboray; Diane E Merry
Journal:  J Biol Chem       Date:  2015-03-20       Impact factor: 5.157

8.  Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration.

Authors:  Andrey S Tsvetkov; Montserrat Arrasate; Sami Barmada; D Michael Ando; Punita Sharma; Benjamin A Shaby; Steven Finkbeiner
Journal:  Nat Chem Biol       Date:  2013-07-21       Impact factor: 15.040

9.  Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules.

Authors:  Emily Mitchell Sontag; Gregor P Lotz; Guocheng Yang; Christopher J Sontag; Brian J Cummings; Charles G Glabe; Paul J Muchowski; Leslie Michels Thompson
Journal:  J Huntingtons Dis       Date:  2012

10.  The interaction of polyglutamine peptides with lipid membranes is regulated by flanking sequences associated with huntingtin.

Authors:  Kathleen A Burke; Karlina J Kauffman; C Samuel Umbaugh; Shelli L Frey; Justin Legleiter
Journal:  J Biol Chem       Date:  2013-04-09       Impact factor: 5.157

View more
  10 in total

1.  Sedimentation Velocity Analysis with Fluorescence Detection of Mutant Huntingtin Exon 1 Aggregation in Drosophila melanogaster and Caenorhabditis elegans.

Authors:  Surin A Kim; Victoria F D'Acunto; Bashkim Kokona; Jennifer Hofmann; Nicole R Cunningham; Emily M Bistline; F Jay Garcia; Nabeel M Akhtar; Susanna H Hoffman; Seema H Doshi; Kathleen M Ulrich; Nicholas M Jones; Nancy M Bonini; Christine M Roberts; Christopher D Link; Thomas M Laue; Robert Fairman
Journal:  Biochemistry       Date:  2017-08-24       Impact factor: 3.162

2.  Deubiquitinase USP7 contributes to the pathogenicity of spinal and bulbar muscular atrophy.

Authors:  Anna Pluciennik; Yuhong Liu; Elana Molotsky; Gregory B Marsh; Bedri Ranxhi; Frederick J Arnold; Sophie St-Cyr; Beverly Davidson; Naemeh Pourshafie; Andrew P Lieberman; Wei Gu; Sokol V Todi; Diane E Merry
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 3.  Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease.

Authors:  Adewale Adegbuyiro; Faezeh Sedighi; Albert W Pilkington; Sharon Groover; Justin Legleiter
Journal:  Biochemistry       Date:  2017-02-21       Impact factor: 3.162

4.  Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases.

Authors:  Riccardo Cristofani; Valeria Crippa; Paola Rusmini; Maria Elena Cicardi; Marco Meroni; Nausicaa V Licata; Gessica Sala; Elisa Giorgetti; Christopher Grunseich; Mariarita Galbiati; Margherita Piccolella; Elio Messi; Carlo Ferrarese; Serena Carra; Angelo Poletti
Journal:  Autophagy       Date:  2017-08-03       Impact factor: 16.016

5.  The 11S Proteasomal Activator REGγ Impacts Polyglutamine-Expanded Androgen Receptor Aggregation and Motor Neuron Viability through Distinct Mechanisms.

Authors:  Jill M Yersak; Heather L Montie; Erica S Chevalier-Larsen; Yuhong Liu; Lan Huang; Martin Rechsteiner; Diane E Merry
Journal:  Front Mol Neurosci       Date:  2017-05-24       Impact factor: 5.639

6.  Polyglutamine-Expanded Androgen Receptor Alteration of Skeletal Muscle Homeostasis and Myonuclear Aggregation Are Affected by Sex, Age and Muscle Metabolism.

Authors:  Mathilde Chivet; Caterina Marchioretti; Marco Pirazzini; Diana Piol; Chiara Scaramuzzino; Maria Josè Polanco; Vanina Romanello; Emanuela Zuccaro; Sara Parodi; Maurizio D'Antonio; Carlo Rinaldi; Fabio Sambataro; Elena Pegoraro; Gianni Soraru; Udai Bhan Pandey; Marco Sandri; Manuela Basso; Maria Pennuto
Journal:  Cells       Date:  2020-01-30       Impact factor: 6.600

Review 7.  Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease.

Authors:  Frederick J Arnold; Diane E Merry
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

8.  A peptide inhibitor that rescues polyglutamine-induced synaptic defects and cell death through suppressing RNA and protein toxicities.

Authors:  Shaohong Isaac Peng; Lok I Leong; Jacquelyne Ka-Li Sun; Zhefan Stephen Chen; Hei-Man Chow; Ho Yin Edwin Chan
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-13       Impact factor: 10.183

9.  Minimotifs dysfunction is pervasive in neurodegenerative disorders.

Authors:  Surbhi Sharma; Richard J Young; Jingchun Chen; Xiangning Chen; Edwin C Oh; Martin R Schiller
Journal:  Alzheimers Dement (N Y)       Date:  2018-07-25

10.  Impaired Nuclear Export of Polyglutamine-Expanded Androgen Receptor in Spinal and Bulbar Muscular Atrophy.

Authors:  Frederick J Arnold; Anna Pluciennik; Diane E Merry
Journal:  Sci Rep       Date:  2019-01-15       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.